Clinical Trial

Lutein Iontophoresis in Intermediate AMD and Reticular Pseudodrusen - a Retrospective Study

Completed
View on ClinicalTrials.gov →
Summary
There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with in-termediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD). This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.
Trial Details
NCT Number NCT07420361
Lead Sponsor Mario Damiano Toro
Conditions Intermediate Age-Related Macular Degeneration With Reticular Pseudodrusen
Enrollment 30 participants
Start Date 2023-08-01
Primary Completion 2024-08-31 (estimated)
Study Completion 2024-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-19